AL8326 high dose group for Small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Small Cell Lung CancerAL8326 high dose group - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to treat small cell lung cancer that has come back or spread. The goal is to see if it is safe and effective.

Eligible Conditions
  • Small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
CVXGA1 low dose
1
ABBV-011
1
PF-06821497

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: 12 month

12 month
Objective Response Rates (ORR)
12 months
Duration of response ( DOR)
Number of participants with AEs, SAEs, abnormal physical examination findings, abnormal laboratory test results, abnormal vital signs and abnormal electrocardiography (ECG) findings
Optimal biological dose ( OBD )

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
CVXGA1 low dose
1
ABBV-011
1
PF-06821497

Trial Design

3 Treatment Groups

OBD finding cohort at high dose
1 of 3
OBD finding cohort at middle dose
1 of 3
OBD finding cohort at low dose
1 of 3

Experimental Treatment

36 Total Participants · 3 Treatment Groups

Primary Treatment: AL8326 high dose group · No Placebo Group · Phase 2

OBD finding cohort at high dose
Drug
Experimental Group · 1 Intervention: AL8326 high dose group · Intervention Types: Drug
OBD finding cohort at middle dose
Drug
Experimental Group · 1 Intervention: AL8326 middle dose group · Intervention Types: Drug
OBD finding cohort at low dose
Drug
Experimental Group · 1 Intervention: AL8326 low dose group · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 month

Who is running the clinical trial?

Advenchen Pharmaceuticals, LLC.Lead Sponsor
Ramaswamy Govindan, MDPrincipal InvestigatorWashington University School of Medicine
6 Previous Clinical Trials
10,758 Total Patients Enrolled
Saiama Waqar, MDPrincipal InvestigatorWashington University School of Medicine
1 Previous Clinical Trials
23 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are a male or female, 18 years of age or older.
You have no symptoms or signs of cancer.
You have at least 1 lesion that meets the criteria for being measurable, as defined by RECIST 1.1.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top